Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice

Veterinary Immunology and Immunopathology

Volumn 131, Issue 3-4, 2009, Pages 158-166

  Zhao, He Ping ^a   Sun, Jian Fu ^a,b   Li, Na ^a   Sun, Yuan ^a   Wang, Yu ^a   Qiu, Hua Ji ^a  

^a Harbin Veterinary Research Institute   (China)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Alphavirus replicon vector; Classical swine fever virus (CSFV); Prime boost; Recombinant adenovirus; Recombinant E2 protein

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PESTIVIRUS; REPLICON; SWINE; SWINE DISEASE; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS IMMUNITY;

ADENOVIRIDAE; ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLASSICAL SWINE FEVER; CLASSICAL SWINE FEVER VIRUS; FEMALE; GENES, VIRAL; GENETIC VECTORS; HERPESVIRUS 1, SUID; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; REPLICON; SUS SCROFA; VACCINES, DNA; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

ADENOVIRIDAE; ALPHAVIRUS; CLASSICAL SWINE FEVER VIRUS; MUS; SUID HERPESVIRUS 1;

EID: 69949129804     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.04.003     Document Type: Article

References (51)

1. Aurisicchio L., Mennuni C., Giannetti P., Calvaruso F., Nuzzo M., Cipriani B., Palombo F., Monaci P., Ciliberto G., and La Monica N. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int. J. Cancer 120 (2007) 2290-2300
2. Beer M., Reimann I., Hoffmann B., and Depner K. Novel marker vaccines against classical swine fever. Vaccine 25 (2007) 5665-5670
3. Belshe R.B., Stevens C., Gorse G.J., Buchbinder S., Weinhold K., Sheppard H., Stablein D., Self S., McNamara J., Frey S., Flores J., Excler J.L., Klein M., Habib R.E., Duliege A.M., Harro C., Corey L., Keefer M., Mulligan M., Wright P., Celum C., Judson F., Mayer K., McKirnan D., Marmor M., Woody G., and National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET). Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 183 (2001) 1343-1352
4. Bird J.J., Brown D.R., Mullen A.C., Moskowitz N.H., Mahowald M.A., Sider J.R., Gajewski T.F., Wang C.R., and Reiner S.L. Helper T cell differentiation is controlled by the cell cycle. Immunity 9 (1998) 229-237
5. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L.G., Ling M., and Wu T.C. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 75 (2001) 2368-2376
6. Cristillo A.D., Wang S., Caskey M.S., Unangst T., Hocker L., He L., Hudacik L., Whitney S., Keen T., Chou T.H., Shen S., Joshi S., Kalyanaraman V.S., Nair B., Markham P., Lu S., and Pal R. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346 (2006) 151-168
7. Dong X.N., and Chen Y.H. Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine 25 (2007) 205-230
8. Dory D., Fischer T., Béven V., Cariolet R., Rziha H.J., and Jestin A. Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus (Herpes suid 1). Vaccine 24 (2006) 6256-6263
9. Dunachie S.J., and Hill A.V. Prime-boost strategies for malaria vaccine development. J. Exp. Biol. 206 (2003) 3771-3779
10. Elliott G., and O'hare P. Intercellular trafficking and protein delivery by aherpesvirus structural protein. Cell 88 (1997) 223-233
11. Estcourt M.J., Ramsay A.J., Brooks A., Thomson S.A., Medveckzy C.J., and Ramshaw I.A. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int. Immunol. 14 (2002) 31-37
12. Frankel A.D., and Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 (1988) 1189-1193
13. Ganges L., Barrera M., Nunez J.I., Blanco I., Frias M.T., Rodríguez F., and Sobrino F. A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge. Vaccine 23 (2005) 3741-3752
14. Gilbert S.C., Moorthy V.S., Andrews L., Pathan A.A., McConkey S.J., Vuola J.M., Keating S.M., Berthoud T., Webster D., McShane H., and Hill A.V. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24 (2006) 4554-4561
15. Green M., and Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55 (1988) 1179-11881
16. Greiser-Wilke I., Blome S., and Moennig V. Diagnostic methods for detection of Classical swine fever virus-status quo and new developments. Vaccine 25 (2007) 5524-5530
17. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18 (2000) 927-974
18. Hammond J.M., Jansen E.S., Morrissy C.J., Goff W.V., Meehan G.C., Williamson M.M., Lenghaus C., Sproat K.W., Andrew M.E., Coupar B.E., and Johnson M.A. A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever. Vet. Microbiol. 80 (2001) 101-119
19. Harms J.S., Ren X., Oliveira S.C., and Splitter G.A. Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations. J. Virol. 74 (2000) 3301-3312
20. Kim S.J., Sung H.W., Han J.H., Jackwood D., and Kwon H.M. Protection against very virulent infectious bursal disease virus in chickens immunized with DNA vaccines. Vet. Microbiol. 101 (2004) 39-51
21. Li N., Qiu H.J., Zhao J.J., Li Y., Wang M.J., Lu B.W., Han C.G., Hou Q., Wang Z.H., Gao H., Peng W.P., Li G.X., Zhu Q.H., and Tong G.Z. A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge. Vaccine 25 (2007) 2907-2912
22. Li N., Zhao J.J., Zhao H.P., Sun Y., Zhu Q.H., Tong G.Z., and Qiu H.J. Protection of pigs from lethal challenge by a DNA vaccine based on an alphavirus replicon expressing the E2 glycoprotein of classical swine fever virus. J. Virol. Methods 144 (2007) 73-78
23. Liang R., van den Hurk J.V., Landi A., Lawman Z., Deregt D., Townsend H., Babiuk L.A., and van Drunen Littel-van den Hurk S. DNA prime protein boost strategies protect cattle from bovine viral diarrhea virus type 2 challenge. J. Gen. Virol. 89 (2008) 453-466
24. Lo C.Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.P., Tumpey T.M., and Epstein S.L. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26 (2008) 2062-2072
25. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin. Immunopathol. 28 (2006) 255-265
26. Mateu de Antonio E., Husmann R.J., Hansen R., Lunney J.K., Strom D., Martin S., and Zuckermann F.A. Quantitative detection of porcine interferon-gamma in response to mitogen, superantigen and recall viral antigen. Vet. Immunol. Immunopathol. 61 (1998) 265-277
27. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Moy R., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., and Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
28. McShane H., Brookes R., Gilbert S.C., and Hill A.V. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69 (2001) 681-686
29. Meyers G., and Thiel H.J. Molecular characterization of pestiviruses. Adv. Virus Res. 47 (1996) 53-118
30. Miyamoto T., Min W., and Lillehoj H.S. Lymphocyte proliferation response during Eimeria tenella infection assessed by new, reliable nonradioactive colorimetric assay. Avian Dis. 46 (2002) 10-16
31. Moennig V. Introduction to classical swine fever virus, disease and control policy. Vet. Microbiol. 73 (2000) 93-102
32. Moormann R.J., van Gennip H.G., Miedema G.K., Hulst M.M., and van Rijn P.A. Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. J. Virol. 70 (1996) 763-770
33. Näslund T.I., Uyttenhove C., Nordström E.K., Colau D., Warnier G., Jondal M., Van den Eynde B.J., and Liljeström P. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 178 (2007) 6761-6769
34. Oliveira S.C., Harms J.S., Afonso R.R., and Splitter G.A. A genetic immunization adjuvant system based on BVP22-antigen fusion. Hum. Gene Ther. 12 (2001) 1353-1359
35. Pal R., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Hocker L., Hudacik L., Rose N., Mboudjeka I., Shen S., Wu-Chou T.H., Montefiori D., Mascola J., Markham P., and Lu S. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348 (2006) 341-353
36. Peng W.P., Xia Z.H., Hou Q., Li N., Sun Y., Tong G.Z., and Qiu H.J. Differences in glycosylation of the E2 protein between virulent Shimen strain and a virulent C-strain of classical swine fever virus. Bing Du Xue Bao 23 (2007) 389-393 (Chinese)
37. Prescott L.M. Microbiology. 5th edition (2002), McGraw Hill, New York p. 336
38. Robinson H.L. Prime boost vaccines power up in people. Nat. Med. 9 (2003) 642-643
39. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., and Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
40. Subramanian S., and Divya Shree A.N. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. Neurosci. Lett. 436 (2008) 219-222
41. Sun, Y., Liu, D.F., Wang, Y.F., Liang, B.B., Cheng, D., Li, N., Qi, Q.F., Zhu, Q.H., Qiu, H.J., in press. Generation and efficacy evaluation of a recombinant adenovirus expressing the E2 protein of classical swine fever virus. Res. Vet. Sci.
42. Sun Y., Xia Z.H., Liang B.B., Peng W.P., and Qiu H.J. Development of an indirect ELISA based on the recombinant E2 protein expressed in baculovirus for detecting antibodies against classical swine fever virus. Chin. Vet. Sci. 38 (2008) 315-319 (Chinese)
43. Tanghe A., D'Souza S., Rosseels V., Denis O., Ottenhoff T.H., Dalemans W., Wheeler C., and Huygen K. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69 (2001) 3041-3047
44. van Oirschot J.T. Vaccinology of classical swine fever: from lab to field. Vet. Microbiol. 96 (2003) 367-384
45. Vinner L., Wee E.G., Patel S., Corbet S., Gao G.P., Nielsen C., Wilson J.M., Ertl H.C., Hanke T., and Fomsgaard A. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J. Gen. Virol. 84 (2003) 203-213
46. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., Laidlaw S.M., Peto T., Skinner M.A., Gilbert S.C., and Hill A.V. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 (2006) 3026-3034
47. Weiss W.R., Kumar A., Jiang G., Williams J., Bostick A., Conteh S., Fryauff D., Aguiar J., Singh M., O'Hagan D.T., Ulmer J.B., and Richie T.L. Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS ONE 2 (2007) e1063
48. Xu J., Mendez E., Caron P.R., Lin C., Murcko M.A., Collett M.S., and Rice C.M. Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication. J. Virol. 71 (1997) 5312-5322
49. + cytotoxic T lymphocytes. J. Immunol. Methods 276 (2003) 45-57
50. Zhao H.P., Sun J.F., Li N., Sun Y., Xia Z.H., Wang Y., and Qiu H.J. Assessment of the cell-mediated immunity induced by alphavirus replicon-vectored DNA vaccines against classical swine fever in a mouse model. Vet. Immunol. Immunopathol. 129 (2009) 57-65
51. Zuckermann F.A., Husmann R.J., Schwartz R., Brandt J., Mateu de Antonio E., and Martin S. Interleukin-12 enhances the virus-specific interferon gamma response of pigs to an inactivated pseudorabies virus vaccine. Vet. Immunol. Immunopathol. 63 (1998) 57-67